REGENXBIO Inc.
RGNX
$7.77
$0.010.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.03% | 39.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.03% | 39.21% | |||
| Cost of Revenue | 6.01% | -4.46% | |||
| Gross Profit | -9.69% | 25.97% | |||
| SG&A Expenses | 10.50% | 1.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -16.92% | 44.44% | |||
| Total Operating Expenses | 7.10% | -2.95% | |||
| Operating Income | -9.97% | 17.17% | |||
| Income Before Tax | -8.41% | 12.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.41% | 12.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.41% | 12.60% | |||
| EBIT | -9.97% | 17.17% | |||
| EBITDA | -10.80% | 18.27% | |||
| EPS Basic | -8.28% | 12.95% | |||
| Normalized Basic EPS | -8.26% | 12.95% | |||
| EPS Diluted | -8.28% | 12.95% | |||
| Normalized Diluted EPS | -8.26% | 12.95% | |||
| Average Basic Shares Outstanding | 0.12% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||